Most Popular
-
1
Opposition-led Assembly unilaterally passes bill to probe Marine's death
-
2
Inflation eases in April, continues bumpy ride
-
3
Golden chance to liquidate babies’ gold rings?
-
4
Seoul to more than double military drones by 2026 to counter NK threats
-
5
Russia sent more than 165,000 barrels of refined petroleum to N. Korea in March: White House
-
6
Seoul alerts overseas missions to NK terror threats
-
7
Over 60% of S. Koreans support W100m childbirth incentive: survey
-
8
‘Inside Out 2’ adds four new emotions, explores teenage life
-
9
Key suspects grilled over alleged abuse of power in Marine death inquiry
-
10
Questions raised over fair promotion of RM, NewJeans
Dream Pharma Corp., a Korean drug maker, will develop new treatment for superbugs to cater to soaring demand for drugs against the fatal bacteria.
The Hanwha-affiliate said Wednesday it clinched a deal with LegoChem Biosciences Inc. for joint research and commercialization of the bioventure’s novel product.
The drug candidate known as LCB01-0371 has been proven superior to Pfizer Inc. Zyvox in treating superbugs, which are resistant to nearly all existing antibiotics, Dream Pharma said.
Clinical trials in the U.S. also showed that the product had almost no side effects like bone marrow suppression, and its high solvency could make it injectable, the company added.
The two partners plan to embark on the first-phase clinical trial at the Asan Medical Center in Seoul in January.
Superbug made headlines last year as it spread to Britain and the U.S. among travelers who had surgery in India. Nearly 20,000 people die each year in the U.S. as a result of their infection with drug-resistant bacteria, data shows. In Korea, some 5,000 patients received related treatment during the first half of the year alone.
The U.S. drug giant’s Zyvox, one of the world’s top-selling antibiotics, generated $1.4 billion in sales last year. Cubist Pharmaceuticals’s Cubicin sold more than $600 million.
“We will aggressively target the global market as demand is expected to grow in China and other countries,” said Lee Je-won, Dream Pharma’s chief developer, valuing the market at 4 trillion won ($3.5 billion) as of end-2010.
By Shin Hyon-hee (heeshin@heraldcorp.com)
The Hanwha-affiliate said Wednesday it clinched a deal with LegoChem Biosciences Inc. for joint research and commercialization of the bioventure’s novel product.
The drug candidate known as LCB01-0371 has been proven superior to Pfizer Inc. Zyvox in treating superbugs, which are resistant to nearly all existing antibiotics, Dream Pharma said.
Clinical trials in the U.S. also showed that the product had almost no side effects like bone marrow suppression, and its high solvency could make it injectable, the company added.
The two partners plan to embark on the first-phase clinical trial at the Asan Medical Center in Seoul in January.
Superbug made headlines last year as it spread to Britain and the U.S. among travelers who had surgery in India. Nearly 20,000 people die each year in the U.S. as a result of their infection with drug-resistant bacteria, data shows. In Korea, some 5,000 patients received related treatment during the first half of the year alone.
The U.S. drug giant’s Zyvox, one of the world’s top-selling antibiotics, generated $1.4 billion in sales last year. Cubist Pharmaceuticals’s Cubicin sold more than $600 million.
“We will aggressively target the global market as demand is expected to grow in China and other countries,” said Lee Je-won, Dream Pharma’s chief developer, valuing the market at 4 trillion won ($3.5 billion) as of end-2010.
By Shin Hyon-hee (heeshin@heraldcorp.com)
-
Articles by Korea Herald
